Compare HSBC Holdings plc (HSBC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? HSBC Holdings plc trades at $94.92 (market cap $322.45B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: HSBC Holdings plc is far larger — about 329.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and HSBC Holdings plc pays a 3.99% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HSBC | MRVI | |
|---|---|---|
Market Cap | $322.45B | $977.37M |
Volume | 2,058,215 | 2,742,564 |
Sector | Financials | Health |
52-Week High | $107.86 | $9.00 |
52-Week Low | $65.67 | $2.83 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.52B | $1.08B |
Dividend Yield | 3.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with mixed technical signals showing bearish momentum but neutral oscillators. The bank demonstrates strong profitability with a 34.54% net income margin and reasonable valuation at 13.42 P/E. Recent strategic moves include expanding US wealth services and re-entering India's equity broking market, while analyst sentiment remains divided with 38% buy ratings.
HSBC presents a balanced opportunity with solid fundamentals and global expansion initiatives, though technical weakness and CFO transition risks warrant caution. The stock's current valuation appears reasonable relative to earnings power, but investors should monitor execution of growth strategies amid competitive banking landscape and potential macroeconomic headwinds.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
